The American Hospital Association (AHA) yesterday asked U.S. House and Senate party leaders to ensure that a must-pass spending bill next month protects hospitals from losing their 340B eligibility due to changes in patient and payer mix caused by the
…
U.S. Senate Finance Committee Chair Ron Wyden (D-Ore.) said this week that new Congressional Budget Office (CBO) findings on brand drug price increases “drive home the urgent need to pass robust drug pricing reforms.”
“The average net price for brand-name
…
Bills have been filed in at least five state legislatures to protect 340B covered entities and their contract pharmacies from discrimination by pharmacy benefit managers (PBMs).
Sixteen states have enacted one or more such laws since 2019, according to
…
In his monthly column for Omnicell’s blog, 340B Report Publisher and Chief Executive Officer Ted Slafsky makes three big predictions for the 340B program for 2022. They focus on:
South Dakota U.S. Sen. John Thune, the second-ranking Senate Republican and a long-time 340B covered entity ally, might not run for re-election in 2022, two news organizations report. It would be a significant blow to 340B providers who have counted
…
U.S. Sen. Joe Manchin (D-W.Va.) has suggested that the U.S. Department of Veterans Affairs (VA) be empowered to negotiate drug prices on behalf of Medicare, an initiative that may impact the 340B program if it should come to fruition.
Manchin
…
West Virginia U.S. Sen. Joe Manchin’s rejection Sunday of his fellow Democrats’ Build Back Better (BBB) policy agenda left its drug pricing section dead in the water.
Manchin said of the BBA bill on Dec. 19, “I cannot vote to
…
The U.S. House Oversight and Reform Committee issued a blistering report late last week accusing brand pharmaceutical manufacturers of systematically jacking up prices on their drugs in the United States.
Pharmaceutical Research and Manufacturers of America (PhRMA) called it a
…
The U.S. Senate Finance Committee’s latest drug pricing legislation includes language, not seen before in earlier House and Senate versions, about denying 340B covered entities’ access to government-negotiated lower prices on drugs covered under Medicare.
The committee released the
*Sign up for news summaries and alerts from 340B Report